塞库金单抗
医学
天疱疮
皮肤病科
大疱性类天疱疮
桥粒胶蛋白3
银屑病
白细胞介素17
免疫学
抗体
银屑病性关节炎
自身抗体
免疫系统
标识
DOI:10.1111/1346-8138.16936
摘要
Abstract Interleukin 17A (IL‐17A) inhibitors, such as secukinumab, have been widely used as the mainstream treatment for chronic plaque psoriasis; however, cutaneous adverse events have been reported. Here, we report a 43‐year‐old Chinese man who developed herpetiform pemphigus (HP) during secukinumab treatment for his psoriasis. He presented with (1) clinical features of HP, which resembled bullous pemphigoid; histopathological features of intraepidermal blisters, eosinophilic/neutrophilic spongiosis, and liquefactive degeneration of the basal cell layer; (3) positive anti‐desmoglein 1 antibody by enzyme‐linked immunosorbent assay and cell surface IgG reactivity within the epidermis by indirect immunofluorescence assay; and (4) a satisfactory response to salicylazosulfapyridine (sulfasalazine). To the best of our knowledge, this is the first report of the development of HP after the use of secukinumab for psoriasis.
科研通智能强力驱动
Strongly Powered by AbleSci AI